Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 419-424

  Bezwada, Padma ^a   Clark, Leslie A ^a   Schneider, Susan ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cornea; Cytotoxicity; Fluoroquinolones; Keratocytes

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BIOASSAY; CELL COUNT; CELL CULTURE; CELL DIVISION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA CELL; CORNEA ENDOTHELIUM; CYTOTOXICITY; ENDOTHELIUM CELL; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; TIME;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BIOLOGICAL ASSAY; CIPROFLOXACIN; CORNEA; CORNEAL STROMA; ENDOTHELIAL CELLS; ENDOTHELIUM, CORNEAL; FLUOROQUINOLONES; HUMANS; OFLOXACIN; QUINOLINES;

EID: 39749159755     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X261005     Document Type: Article

References (17)

1. Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005;4:299-309
2. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003;36:1404-10
3. Mallari PLT, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol 2001;131:131-3
4. Reviglio VE, Hakim MA, Song JK, O'Brien TP. Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol 2003;3:10
5. Lindstrom RL. Advances in corneal preservation. Trans Am Ophthalmol Soc 1990;88:555-648
6. Means TL, Geroski DH, Hadley A, et al. Viability of human corneal endothelium following Optisol-GS storage. Arch Ophthalmol 1995;113:805-9
7. Somodi S, Guthoff R. Visualization of keratocytes in the human cornea with fluorescence microscopy. Ophthalmologe 1995;92:452-7
8. Gootz TD, McGuirk PR, Moynihan MS, Haskell SL. Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase. Antimicrob Agents Chemother 1994;38:130-3
9. Hoshino K, Sato K, Akahane K, et al. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother 1991;35:309-12
10. Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother 1998;42:2678-81
11. Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 2004;30:90-4
12. Matsumoto S, Way W, Tarlo K, Short B. Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitro. Cornea 2006;25(Suppl 2):S1-7
13. Snyder MC, Bergmanson JP, Doughty MJ. Keratocytes: no more the quiet cells. J Am Optom Assoc 1998;69:180-7
14. Joyce NC. Cell cycle status in human corneal endothelium. Exp Eye Res 2005;81:629-38
15. Healy DP, Holland EJ, Nordlund ML, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea 2004;23:255-63
16. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol 2005;123:1282-3
17. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50(Suppl 1):S32-45